The latest news about Samsung Bioepis
• Wins a prestigious Biosimilar Initiative of the Year at the Global Generics & Biosimilars Awards 2020
• Recognized for its outstanding achievements and setting new milestones to prove its leadership in biosimilar industry over the past year
INCHEON, KOREA – November 05, 2020 – Samsung Bioepis Co., Ltd. is pleased to announce that it won a prestigious Biosimilar Initiative of the Year at the ‘Global Generics & Biosimilars Awards 2020’ held on November 03, 2020.
“We are honored and thrilled to be receiving the Biosimilar Initiative of the Year award. This award is a testament of the tremendous work that we’ve put towards realizing our vision and commitment to become a globally recognized biopharmaceutical company delivering high-quality medicines to the people who need them the most”, said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. “We will continue to put our passion for health to work and strive for constant innovation so that patients around the globe have access to the high-quality medicines they need.”
Biosimilar Initiative of the Year is given to a company with any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
Samsung Bioepis has been recognized for its outstanding achievements and setting new milestones to prove its leadership in biosimilar industry over the past year. In 2019 alone, the company has continued its global market expansion in Asia and Latin America, while its first oncology product ONTRUZANT® (trastuzumab) became the first biosimilar to be prequalified by the World Health Organization (WHO), increasing worldwide access to life-saving breast cancer treatment.
The Global Generics & Biosimilars Awards are presented annually by the international publishing company Informa in cooperation with IQVIA. This year the event was held virtually to reward ‘best practice’ across the generics, biosimilars and value-added medicine industries, while at the same time encouraging improvements in every aspect of the way business is conducted.
In just eight years of establishment, Samsung Bioepis has five products approved and marketed in Europe in immunology and oncology, and the immunology products have treated over 215,000 patients in Europe alone.
# # #
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.
Yoon Kim: +82-31-8061-3926, firstname.lastname@example.org